XBiotech continues to consider other possible oncology indications for Xilonix, particularly as a combination therapy. The Company believes Xilonix may work, for example, to improve the efficacy of chemotherapy where immunomodulatory effects of treatment may be partly related to disease progression. XBiotech is confident in Xilonix’s potential as both a monotherapy and as a combination therapy for the treatment of various types of cancer and will continue to explore these treatment opportunities.
There remains interest to assess Xilonix in combination with Tarceva® for the treatment of NSCLC. The interest in combining Xilonix with an EGFR inhibitor was based on results, which we published in Investigational New Drugs recently, of treatment for non-small cell lung cancer patients who have previously been treated with an EGFR inhibitor. Patients receiving anti-EGFR therapy prior to Xilonix had considerably better outcomes than those that had not received EGFR inhibition. We will continue to look for opportunities in combination therapy for non-small cell lung cancer and other indications involving anti EGFR treatment.